Evaluation of the role of spectral-domain optical coherence tomography in the early detection of macular and ganglion cell complex thickness changes in patients with rheumatologic diseases taking hydroxychloroquine.

Autor: Aydın Kurna S; Department of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, Health Science University, Hastane Sokak no:1/8. İçerenköy, Ataşehir, İstanbul 34752, Türkiye. Electronic address: seydaydin@yahoo.com., Kanar HS; Department of Ophthalmology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Health Science University, Cevizli, D-100 Güney Yanyol, Cevizli Mevkii No:47, Kartal, İstanbul 34865, Türkiye. Electronic address: hselensonmez@hotmail.com., Garlı M; Department of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, Health Science University, Hastane Sokak no:1/8. İçerenköy, Ataşehir, İstanbul 34752, Türkiye. Electronic address: muratgarli@hotmail.com., Çakır N; Department of Rheumatology, Fatih Sultan Mehmet Training and Research Hospital, Health Science University, Hastane Sokak no: 1/8. İçerenköy, Ataşehir, İstanbul 34752, Türkiye. Electronic address: necaticakir@hotmail.com.
Jazyk: angličtina
Zdroj: Photodiagnosis and photodynamic therapy [Photodiagnosis Photodyn Ther] 2022 Jun; Vol. 38, pp. 102741. Date of Electronic Publication: 2022 Jan 31.
DOI: 10.1016/j.pdpdt.2022.102741
Abstrakt: Background: The aim was to investigate the effects of hydroxychloroquine (HCQ) on macular and ganglion cell complex (GCC) thickness measured by spectral-domain optical coherence tomography (SD-OCT).
Methods: A total of 145 patients were included in the study. Patients who had taken HCQ for at least 6 months formed group 1 (n:81), while 34 patients with rheumatologic diseases who did not receive HCQ therapy, and 30 healthy subjects formed groups 2 and 3. The patients in group 1 were divided into two subgroups one with more than 60 months of usage (A), and the other with less than 60 months (B). All patients underwent a complete ophthalmologic examination, as well as visual field (VF) testing, and the measurement of macular and GCC thickness with SD-OCT.
Results: The mean duration of taking HCQ was 100.96±46.97 and 26.50±14.45 months and the total dose was 843.37±489.38 g and 208.63±135.01 g in groups 1A and 1B, respectively. Patients in group 1 had significantly worse VF scores than groups 2 and 3, but no difference was found between groups 1A and 1B. The SD-OCT macular thickness was thinner in the inner and outer nasal quadrants according to the ETDRS 9 sector chart in the patients using hydroxychloroquine, while the GCC in the group 1A patients was thinner in the superior, inferior areas and inferior inner nasal, inferior-superior outer temporal quadrants compared to the other groups (p < 0.05).
Conclusion: Assessment of regional macular and GCC changes by SD-OCT is a valuable tool for early detection of HCQ maculopathy.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: